CITIUS ONCOLOGY INC
CTORNASDAQ🏆 #4251 by market capEarnings Dec 21US Equity
——
Quote unavailableTrack CTOR
Get earnings, price moves & breaking news on Telegram
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$54M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
53.1%
Healthy
💵FCF Margin
-277.3%
Thin
⚖️P/S Ratio
7.5x
Fair
Otter Score
—
Insufficient data
No chart data available for CTOR.
Trading Snapshot
- Day Range
- —
- 52-Week Range
- $0.49 – $1.93
- Volume (shares)
- —
- Avg Volume (shares)
- —
- Shares Outstanding
- 93.0M
- Next Earnings
- 2026-12-21
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -1.2
- P/S Ratio
- 7.5x
- EPS (TTM)
- $-0.43
- Dividend Yield
- 0.00%
CITIUS ONCOLOGY INC
CTORFinancial Trends
Financial history unavailable.
StockOtter · stockotter.spaceAbout CITIUS ONCOLOGY INC
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.